- Home
- RDI vs ALGS Comparison
RDI vs ALGS Comparison
Compare RDI & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | ALGS |
|---|---|---|
| Founded | 1937 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 34.6M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDI | ALGS |
|---|---|---|
| Price | $1.72 | $6.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 74.8K | ★ 144.3K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.76 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $202,988,000.00 | $2,186,000.00 |
| Revenue This Year | $16.25 | $32.20 |
| Revenue Next Year | $4.04 | $4.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.94 | $3.98 |
| 52 Week High | $1.77 | $13.69 |
Technical Indicators
Market Signals| Indicator | RDI | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 69.71 | 63.00 |
| Support Level | $1.00 | $6.25 |
| Resistance Level | N/A | $7.05 |
| Average True Range (ATR) | 0.09 | 0.65 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 88.64 | 77.25 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.